The ultrasound examination was recorded using a Toshiba Sonolayer SSA-90A and Toshiba video recorder among participants aged 20 to 74 years in NHANES Ⅲ between 1988 and 1994. In 2009–2010, archived gall bladder ultrasound video images were reviewed to assess the presence of fat within the hepatic parenchyma using standard criteria. Followed by the five criteria (liver to kidney contrast; brightness of the liver parenchyma; deep beam attenuation; echogenic walls in the small intrahepatic vessels; the definition of the gallbladder walls), hepatic steatosis (HS) was categorized as normal, mild, moderate, or severe. In order to avoid potential overlap between mild and moderate hepatic steatosis, a categorization of fatty liver disease as “yes” or “no” was generally used. “Yes” indicated moderate or severe hepatic steatosis, while “No” indicated the liver was normal or had mild hepatic steatosis(27 ).
Sonolayer ssa 90a
Manufactured by Toshiba
Sourced in Japan
The Sonolayer SSA-90A is a laboratory instrument designed for ultrasonic analysis. It is capable of performing measurements and characterization of various materials and samples using ultrasonic techniques.
Automatically generated - may contain errors
Lab products found in correlation
6 protocols using sonolayer ssa 90a
1
Hepatic Steatosis Evaluation in NHANES III
2
Non-Alcoholic Fatty Liver Disease Diagnosis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NAFLD was identified by the presence of mild, moderate, or severe hepatic steatosis on ultrasound (hepatic ultrasound video images using the Toshiba Sonolayer SSA‐90A and Toshiba video recorders; detailed information on methodology and quality control are described elsewhere23 ) in the absence of other causes of chronic liver disease (alcohol consumption <20 g/day for male participants and <10 g/day for female participants, hepatitis B surface antigen negative, anti‐hepatitis C virus antibody negative, transferrin saturation <50%).
3
Fatty Liver Diagnosis via Ultrasound
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The presence of fatty liver was determined by the Hepatic Steatosis Ultrasound Examination performed in NHANES III participants with the Toshiba Sonolayer SSA-90A (Toshiba America Medical Systems, Tustin, CA) 19 using 5 different parameters: liver-to-kidney contrast, liver parenchymal brightness, bright vessel walls, deep beam attenuation, and gallbladder wall definition. 20 The ultrasonographic evaluation of the liver was reported as normal, mild, moderate, or severe hepatic steatosis. The interrater reliability between readers for the 4 levels grading had only 75% agreement (kappa ¼ 0.58). 20 Steatosis was also reported as a dichotomous variable: present (moderate or severe steatosis) or absent (normalmild steatosis). The interrater reliability between readers for the dichotomous hepatic steatosis grading had 88.7% agreement (kappa ¼ 0.70). 20 Based on this reason and studies by others, [21] [22] [23] [24] [25] [26] participants in our study were considered to have fatty liver if moderate to severe hepatic steatosis was noted. Fibrosis-4 index (FIB-4) was calculated using published formula, 27 and FIB-4 index >2.67 defined advanced fibrosis. 28
4
Hepatic Steatosis Evaluation Using Ultrasound
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The ultrasound examination was recorded using a Toshiba Sonolayer SSA-90A and Toshiba video recorder among participants aged 20 to 74 years in NHANES III between 1988 and 1994. In 2009–2010, archived gall bladder ultrasound video images were reviewed to assess the presence of fat within the hepatic parenchyma using standard criteria. Using five criteria (liver to kidney contrast; brightness of the liver parenchyma; deep beam attenuation; echogenic walls in the small intrahepatic vessels; and the definition of the gallbladder walls), hepatic steatosis was categorized as normal, mild, moderate, or severe. In order to avoid potential overlap between mild and moderate hepatic steatosis, a categorization of hepatic steatosis as “yes” or “no” was generally used. “Yes” indicates moderate or severe hepatic steatosis, while “No” indicates the liver was normal or had mild hepatic steatosis42 .
5
Diagnosis of Metabolic-Associated Fatty Liver Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Participants 25–74 years old underwent gallbladder ultrasound (Toshiba Sonolayer SSA‐90A, Tokyo, Japan), for which images were recorded and reassessed in 2009 and 2010 for the presence and grade of hepatic steatosis as described extensively elsewhere.12 ,14 ,15
MAFLD was defined as steatosis (irrespective of the gradation) combined with metabolic dysfunction. This comprises either overweight (BMI, ≥25 kg/m2), type 2 diabetes mellitus (defined as antidiabetic drug use, fasting plasma glucose ≥7.0 mmol/L, glycated hemoglobin [HbA1c] > 6.4%, or based on the oral glucose tolerance test [OGTT]), or a combination of at least two of the following metabolic abnormalities: (1) waist circumference > 102 cm for males and >88 cm for females; (2) blood pressure ≥ 130/85 mm Hg or antihypertensive drug use; (3) plasma triglycerides ≥1.70 mmol/L or lipid‐lowering drug treatment; (4) HDL cholesterol (HDL‐C) <1.0 mmol/L for males and <1.3 mmol/L for females or lipid‐lowering drug treatment; (5) prediabetes defined as fasting plasma glucose 5.6–6.9 mmol/L, HbA1c 5.7%–6.4%, or matching OGTT; (6) homeostatic model assessment of insulin resistance ≥2.5; or (7) C‐reactive protein (CRP) level > 2 mg/L.1 (link)
MAFLD was defined as steatosis (irrespective of the gradation) combined with metabolic dysfunction. This comprises either overweight (BMI, ≥25 kg/m2), type 2 diabetes mellitus (defined as antidiabetic drug use, fasting plasma glucose ≥7.0 mmol/L, glycated hemoglobin [HbA1c] > 6.4%, or based on the oral glucose tolerance test [OGTT]), or a combination of at least two of the following metabolic abnormalities: (1) waist circumference > 102 cm for males and >88 cm for females; (2) blood pressure ≥ 130/85 mm Hg or antihypertensive drug use; (3) plasma triglycerides ≥1.70 mmol/L or lipid‐lowering drug treatment; (4) HDL cholesterol (HDL‐C) <1.0 mmol/L for males and <1.3 mmol/L for females or lipid‐lowering drug treatment; (5) prediabetes defined as fasting plasma glucose 5.6–6.9 mmol/L, HbA1c 5.7%–6.4%, or matching OGTT; (6) homeostatic model assessment of insulin resistance ≥2.5; or (7) C‐reactive protein (CRP) level > 2 mg/L.1 (link)
6
Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Hepatic steatosis was recorded by ultrasound (Toshiba Sonolayer SSA-90A) and evaluated using the following five parameters (liver to kidney contrast, parenchymal brightness, bright vessel walls, deep beam attenuation, and gallbladder wall definition) by three trained ultrasound readers. The degree of hepatic steatosis was graded as normal, mild, moderate, or severe.
MAFLD was defined as the presence of hepatic steatosis (mild to severe) with one or more of the following: (i) overweight or obese (body mass index ≥ 25 kg/m2); (ii) type 2 diabetes (fasting plasma glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% or the use of anti-hyperglycemic agents); or (iii) at least 2 metabolic abnormalities described by any two indicators: (a) waist circumference (WC) ≥ 102 cm in men or ≥ 88 cm in women; (b) blood pressure ≥ 130/85 mmHg or taking anti-hypertension drugs; (c) raised triglycerides (≥ 1.70 mmol/L); (d) reduced HDL cholesterol (plasma HDL < 1.0 mmol/L for men and < 1.3 mmol/L for women); (e) prediabetes status (FPG 5.6–6.9 mmol/L, or 2-h post-load glucose levels 7.8–11.0 mmol or HbA1c 5.7–6.4%); (f) HOMA-IR ≥ 2.5; (g) plasma C-reactive protein (CRP) level > 2 mg/L [3 (link)].
Blood samples for SUA measurement were measured by uricase-mediated oxidation to form allantoin and hydrogen peroxide (Hitachi 737 Analyzer), and data were rounded 1 decimal places (0.1 mg/dL) [22 ].
MAFLD was defined as the presence of hepatic steatosis (mild to severe) with one or more of the following: (i) overweight or obese (body mass index ≥ 25 kg/m2); (ii) type 2 diabetes (fasting plasma glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% or the use of anti-hyperglycemic agents); or (iii) at least 2 metabolic abnormalities described by any two indicators: (a) waist circumference (WC) ≥ 102 cm in men or ≥ 88 cm in women; (b) blood pressure ≥ 130/85 mmHg or taking anti-hypertension drugs; (c) raised triglycerides (≥ 1.70 mmol/L); (d) reduced HDL cholesterol (plasma HDL < 1.0 mmol/L for men and < 1.3 mmol/L for women); (e) prediabetes status (FPG 5.6–6.9 mmol/L, or 2-h post-load glucose levels 7.8–11.0 mmol or HbA1c 5.7–6.4%); (f) HOMA-IR ≥ 2.5; (g) plasma C-reactive protein (CRP) level > 2 mg/L [3 (link)].
Blood samples for SUA measurement were measured by uricase-mediated oxidation to form allantoin and hydrogen peroxide (Hitachi 737 Analyzer), and data were rounded 1 decimal places (0.1 mg/dL) [22 ].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!